Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Jan

Showing results (231-240 of 255) with videos related to

Pageof 26
Sort By:
BMC Cancer|March 8, 2020
Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort studyXiaobin Zhang, Ben M Eyck, Yang Yang, et al.
Annals of Surgery|January 15, 2011
Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancerMark van Heijl, Jikke M Omloo, Mark I van Berge Henegouwen, et al.
International Journal of Cancer|October 17, 2022
Patient preferences for active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in oesophageal cancer treatment: The NOSANO-studyMerel Hermus, Berend J van der Wilk, Rebecca T H Chang, et al.
Annals of Surgery|January 22, 2015
International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG)Donald E Low, Derek Alderson, Ivan Cecconello, et al.
Annals of Surgical Oncology|October 23, 2025
Accuracy of Predicting Residual Disease and Disease Progression During Active Surveillance for Esophageal CancerSanjiv S G Gangaram Panday, David van Klaveren, Sjoerd M Lagarde, et al.
Endoscopy|June 7, 2022
Bite-on-bite biopsies for the detection of residual esophageal cancer after neoadjuvant chemoradiotherapyRuben D van der Bogt, Berend J van der Wilk, Lindsey Oudijk, et al.
The Lancet. Oncology|June 5, 2018
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort studyBo Jan Noordman, Manon C W Spaander, Roelf Valkema, et al.
Endoscopy International Open|August 27, 2025
Safety of surveillance endoscopy and EUS of the esophagus after neoadjuvant chemoradiotherapy: Results from the (pre)SANO trialSanjiv S G Gangaram Panday, Low Kuan Yean, Tanya M Bisseling, et al.
The British Journal of Surgery|July 7, 2023
Active surveillance of oesophageal cancer after response to neoadjuvant chemoradiotherapy: dysphagia is uncommonMaria J Valkema, Manon C W Spaander, Jurjen J Boonstra, et al.
BMC Medical Physics|August 2, 2008
NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial)Mark van Heijl, Jikke M T Omloo, Mark I van Berge Henegouwen, et al.
Pageof 26

Showing results (231-240 of 255) with videos related to

Sort By:
Pageof 26
BMC Cancer|March 8, 2020
Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort studyXiaobin Zhang, Ben M Eyck, Yang Yang, et al.
Annals of Surgery|January 15, 2011
Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancerMark van Heijl, Jikke M Omloo, Mark I van Berge Henegouwen, et al.
International Journal of Cancer|October 17, 2022
Patient preferences for active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in oesophageal cancer treatment: The NOSANO-studyMerel Hermus, Berend J van der Wilk, Rebecca T H Chang, et al.
Annals of Surgery|January 22, 2015
International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG)Donald E Low, Derek Alderson, Ivan Cecconello, et al.
Annals of Surgical Oncology|October 23, 2025
Accuracy of Predicting Residual Disease and Disease Progression During Active Surveillance for Esophageal CancerSanjiv S G Gangaram Panday, David van Klaveren, Sjoerd M Lagarde, et al.
Endoscopy|June 7, 2022
Bite-on-bite biopsies for the detection of residual esophageal cancer after neoadjuvant chemoradiotherapyRuben D van der Bogt, Berend J van der Wilk, Lindsey Oudijk, et al.
The Lancet. Oncology|June 5, 2018
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort studyBo Jan Noordman, Manon C W Spaander, Roelf Valkema, et al.
Endoscopy International Open|August 27, 2025
Safety of surveillance endoscopy and EUS of the esophagus after neoadjuvant chemoradiotherapy: Results from the (pre)SANO trialSanjiv S G Gangaram Panday, Low Kuan Yean, Tanya M Bisseling, et al.
The British Journal of Surgery|July 7, 2023
Active surveillance of oesophageal cancer after response to neoadjuvant chemoradiotherapy: dysphagia is uncommonMaria J Valkema, Manon C W Spaander, Jurjen J Boonstra, et al.
BMC Medical Physics|August 2, 2008
NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial)Mark van Heijl, Jikke M T Omloo, Mark I van Berge Henegouwen, et al.
Pageof 26